摘要
目的:探讨冠心病患者及其服用阿司匹林前后血小板表面糖蛋白的变化及其意义。方法:采用流式细胞仪(flow cy-tometry,FCM)测定冠心病患者阿司匹林治疗前后的全血中血小板表面糖蛋白(CD62p/PAC-1)的表达率,采用自身对照分析阿司匹林对血小板表面糖蛋白的影响。结果:冠心病组治疗前的血小板表面糖蛋白PAC-1、CD62p的表达率分别为(10.4±6.2)%和(10.7±7.1)%,较健康对照组明显升高(P<0.01),经以阿司匹林为基础的抗血小板治疗后CD62p、PAC-1的表达率下降至(4.3±2.1)%和(4.9±2.4)%(P<0.01),但仍高于健康对照组。结论:CD62p和PAC-1是血小板活化的敏感和特异指标,阿司匹林能够抑制血小板表面糖蛋白的表达,从而抑制血小板活化,抑制血栓形成。
OBJECTIVE To explore the changes of platelet activation glycoprotein before and after treatment and the clinical significance in the patients with coronary heart diseases. METHODS CD62p,PAC-1 from whole blood samples were measured by FCM in 22 normal people and 38 patients with CHD before and after treatment. RESULTS Before treatment the percentage of CD62p positive and PAC-1 positive platelet were （ 10. 4 ± 6. 2）% and （ 10. 7 ± 7. 1 ）%, respectively, and were significantly higher than those of normal control（P〈0.0l ）. After treatment the percentage of CD62p positive and PAC-1 positive platelet were （4. 3 ± 2. 1 ）% and （4. 9 ± 2. 4）% respectively and were declined evidently than those before treatment （P〈0.01 ）, but still higher than those of normal control （P〈0.01 ）. CONCLUSION Platelet activation plays an important role in the pathogenesis of coronary heart diseases. CD62p and PAC 1 is the sensitive index of platelet activation. Aspirin can inhibit the express of platelet activation glycoprotein. The detection of platelet function by FCM can be used for the evaluation of thromboembolic disease.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2007年第2期164-167,共4页
Chinese Journal of Hospital Pharmacy
基金
2005年广东省科技厅基金(编号:53064)
2004年广州市医药卫生科技重点项目资助(编号:2004Z006)
